Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals Shares Outstanding 2010-2025 | IRWD

Ironwood Pharmaceuticals shares outstanding from 2010 to 2025. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  
Ironwood Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2024 160
2023 155
2022 186
2021 164
2020 161
2019 156
2018 153
2017 149
2016 145
2015 142
2014 137
2013 116
2012 106
2011 100
2010 90
2009 7
Ironwood Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2025-03-31 161
2024-12-31 160
2024-09-30 160
2024-06-30 159
2024-03-31 158
2023-12-31 155
2023-09-30 187
2023-06-30 155
2023-03-31 187
2022-12-31 186
2022-09-30 184
2022-06-30 185
2022-03-31 190
2021-12-31 164
2021-09-30 165
2021-06-30 163
2021-03-31 162
2020-12-31 161
2020-09-30 160
2020-06-30 160
2020-03-31 160
2019-12-31 156
2019-09-30 157
2019-06-30 156
2019-03-31 155
2018-12-31 153
2018-09-30 153
2018-06-30 152
2018-03-31 151
2017-12-31 149
2017-09-30 150
2017-06-30 149
2017-03-31 148
2016-12-31 145
2016-09-30 145
2016-06-30 145
2016-03-31 144
2015-12-31 142
2015-09-30 142
2015-06-30 142
2015-03-31 141
2014-12-31 137
2014-09-30 139
2014-06-30 138
2014-03-31 130
2013-12-31 116
2013-09-30 121
2013-06-30 113
2013-03-31 108
2012-12-31 106
2012-09-30 114
2012-06-30 107
2012-03-31 104
2011-12-31 100
2011-09-30 100
2011-06-30 100
2011-03-31 99
2010-12-31 90
2010-09-30 98
2010-06-30 98
2010-03-31 64
2009-12-31 7
2009-09-30 7
2009-06-30 7
2009-03-31 7
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.114B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $80.630B 30.25
Zoetis (ZTS) United States $69.973B 26.11
Takeda Pharmaceutical (TAK) Japan $46.997B 9.35
Daiichi Sankyo, - (DSNKY) Japan $42.922B 22.00
BeOne Medicines - (ONC) Cayman Islands $27.080B 0.00
Sandoz Group AG (SDZNY) Switzerland $23.434B 0.00
Merck (MKKGY) Germany $16.421B 12.03
Summit Therapeutics (SMMT) United States $15.269B 0.00
Shionogi (SGIOY) Japan $14.428B 0.00
United Therapeutics (UTHR) United States $13.115B 11.60
Neurocrine Biosciences (NBIX) United States $12.524B 42.90
Orion OYJ (ORINY) Finland $10.594B 28.65
IPSEN (IPSEY) France $9.831B 0.00
Corcept Therapeutics (CORT) United States $7.569B 61.53
Stevanato Group S.p.A (STVN) Italy $7.053B 43.13
Madrigal Pharmaceuticals (MDGL) United States $6.344B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Grifols, S.A (GRFS) Spain $6.030B 0.00
Ionis Pharmaceuticals (IONS) United States $5.954B 0.00
Ono Pharmaceutical (OPHLF) Japan $5.031B 15.30
Soleno Therapeutics (SLNO) United States $4.031B 0.00
Hypermarcas (HYPMY) Brazil $3.075B 20.23
Crinetics Pharmaceuticals (CRNX) United States $2.824B 0.00
Catalyst Pharmaceuticals (CPRX) United States $2.742B 9.61
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.451B 13.25
BioCryst Pharmaceuticals (BCRX) United States $2.113B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.016B 0.00
Indivior (INDV) United States $1.932B 8.19
Centessa Pharmaceuticals (CNTA) United Kingdom $1.660B 0.00
Endo (NDOI) United States $1.595B 0.00
ARS Pharmaceuticals (SPRY) United States $1.552B 0.00
Evotec AG (EVO) Germany $1.335B 0.00
Ocular Therapeutix (OCUL) United States $1.295B 0.00
Guardian Pharmacy Services (GRDN) United States $1.272B 0.00
Dyne Therapeutics (DYN) United States $1.173B 0.00
Harrow (HROW) United States $1.125B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.050B 21.00
Enliven Therapeutics (ELVN) United States $1.045B 0.00
Verve Therapeutics (VERV) United States $0.986B 0.00
Akebia Therapeutics (AKBA) United States $0.967B 0.00
Collegium Pharmaceutical (COLL) United States $0.958B 5.17
Avadel Pharmaceuticals (AVDL) Ireland $0.888B 0.00
Ardelyx (ARDX) United States $0.852B 0.00
Elite Pharmaceuticals (ELTP) United States $0.793B 0.00
Cronos Group (CRON) Canada $0.717B 0.00
Xeris Biopharma Holdings (XERS) United States $0.705B 0.00
Xencor (XNCR) United States $0.608B 0.00
KalVista Pharmaceuticals (KALV) United States $0.604B 0.00
Altimmune (ALT) United States $0.570B 0.00
USANA Health Sciences (USNA) United States $0.569B 12.37
Relay Therapeutics (RLAY) United States $0.547B 0.00
Regulus Therapeutics (RGLS) United States $0.546B 0.00
Bioventus (BVS) United States $0.538B 13.65
Theravance Biopharma (TBPH) United States $0.532B 0.00
AleAnna (ANNA) United States $0.504B 0.00
Zevra Therapeutics (ZVRA) United States $0.494B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.450B 0.00
Oruka Therapeutics (ORKA) United States $0.437B 0.00
Siga Technologies (SIGA) United States $0.437B 9.13
Tourmaline Bio (TRML) United States $0.427B 0.00
Organogenesis (ORGO) United States $0.410B 0.00
Liminatus Pharma (LIMN) United States $0.375B 0.00
Savara (SVRA) United States $0.356B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.338B 9.14
Aquestive Therapeutics (AQST) United States $0.323B 0.00
Heron Therapeutics (HRTX) United States $0.305B 0.00
Nature's Sunshine Products (NATR) United States $0.271B 24.86
Tonix Pharmaceuticals Holding (TNXP) United States $0.238B 0.00
Esperion Therapeutics (ESPR) United States $0.212B 0.00
Nanobiotix S.A (NBTX) France $0.211B 0.00
MediWound (MDWD) Israel $0.206B 0.00
OmniAb (OABI) United States $0.194B 0.00
ProKidney (PROK) United States $0.193B 0.00
4D Molecular Therapeutics (FDMT) United States $0.191B 0.00
Profound Medical (PROF) Canada $0.191B 0.00
Aldeyra Therapeutics (ALDX) United States $0.183B 0.00
Larimar Therapeutics (LRMR) United States $0.166B 0.00
Aclaris Therapeutics (ACRS) United States $0.157B 0.00
Galectin Therapeutics (GALT) United States $0.153B 0.00
Journey Medical (DERM) United States $0.152B 0.00
Innate Pharma SA (IPHYF) France $0.145B 0.00
Avita Medical (RCEL) United States $0.137B 0.00
VAXART, INC (VXRT) United States $0.132B 0.00
Lexeo Therapeutics (LXEO) United States $0.130B 0.00
Lyell Immunopharma (LYEL) United States $0.129B 0.00
Inhibikase Therapeutics (IKT) United States $0.123B 0.00
Protara Therapeutics (TARA) United States $0.118B 0.00
Achieve Life Sciences (ACHV) Canada $0.116B 0.00
Korro Bio (KRRO) United States $0.116B 0.00
Champions Oncology (CSBR) United States $0.115B 18.84
Nektar Therapeutics (NKTR) United States $0.106B 0.00
Fractyl Health (GUTS) United States $0.105B 0.00
Cardiol Therapeutics (CRDL) Canada $0.102B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.101B 0.00
Cassava Sciences (SAVA) United States $0.096B 0.00
Wellgistics Health (WGRX) United States $0.087B 0.00
Nutriband (NTRB) United States $0.087B 0.00
Surrozen (SRZN) United States $0.086B 0.00
Dominari Holdings (DOMH) United States $0.083B 0.00
Arch Biopartners (ACHFF) Canada $0.083B 0.00
Unicycive Therapeutics (UNCY) United States $0.080B 0.00
ESSA Pharma (EPIX) Canada $0.077B 0.00
Vivani Medical (VANI) United States $0.075B 0.00
Pyxis Oncology (PYXS) United States $0.072B 0.00
Inotiv (NOTV) United States $0.070B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.065B 48.33
Assertio Holdings (ASRT) United States $0.060B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
PMV Pharmaceuticals (PMVP) United States $0.057B 0.00
NRx Pharmaceuticals (NRXP) United States $0.056B 0.00
Rafael Holdings (RFL) United States $0.055B 0.00
Metagenomi (MGX) United States $0.054B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.054B 0.00
Gain Therapeutics (GANX) United States $0.053B 0.00
Telomir Pharmaceuticals (TELO) United States $0.052B 0.00
Context Therapeutics (CNTX) United States $0.051B 0.00
Avalo Therapeutics (AVTX) United States $0.050B 0.00
Century Therapeutics (IPSC) United States $0.050B 0.00
Klotho Neurosciences (KLTO) United States $0.050B 0.00
Prelude Therapeutics (PRLD) United States $0.049B 0.00
Mural Oncology (MURA) Ireland $0.042B 0.00
Iterum Therapeutics (ITRM) Ireland $0.040B 0.00
ElectroCore (ECOR) United States $0.038B 0.00
Karyopharm Therapeutics (KPTI) United States $0.038B 0.00
Acrivon Therapeutics (ACRV) United States $0.037B 0.00
Jupiter Neurosciences (JUNS) United States $0.037B 0.00
PolyPid (PYPD) Israel $0.033B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.033B 0.00
China SXT Pharmaceuticals (SXTC) China $0.029B 0.00
SCYNEXIS (SCYX) United States $0.029B 0.00
Enlivex Therapeutics (ENLV) Israel $0.026B 0.00
Tempest Therapeutics (TPST) United States $0.025B 0.00
FibroGen (FGEN) United States $0.023B 0.00
Relmada Therapeutics (RLMD) United States $0.023B 0.00
DURECT (DRRX) United States $0.021B 0.00
Natural Alternatives (NAII) United States $0.020B 0.00
BioVie (BIVI) United States $0.019B 0.00
Mannatech (MTEX) United States $0.019B 0.00
Carisma Therapeutics (CARM) United States $0.018B 0.00
BioLineRx (BLRX) Israel $0.018B 0.00
Ernexa Therapeutics (ERNA) United States $0.018B 0.00
Lipocine (LPCN) United States $0.018B 0.00
Vivos Therapeutics (VVOS) United States $0.016B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.016B 0.00
CASI Pharmaceuticals (CASI) China $0.016B 0.00
ProPhase Labs (PRPH) United States $0.014B 0.00
Lyra Therapeutics (LYRA) United States $0.014B 0.00
VYNE Therapeutics (VYNE) United States $0.014B 0.00
TherapeuticsMD (TXMD) United States $0.013B 0.00
Cosmos Health (COSM) United States $0.012B 0.00
Minerva Neurosciences (NERV) United States $0.012B 2.16
Scienture Holdings (SCNX) United States $0.012B 0.00
Citius Pharmaceuticals (CTXR) United States $0.011B 0.00
Phio Pharmaceuticals (PHIO) United States $0.011B 0.00
Mangoceuticals (MGRX) United States $0.011B 0.00
Ainos (AIMD) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.010B 0.00
GlycoMimetics (CBIO) United States $0.010B 0.00
Talphera (TLPH) United States $0.009B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.009B 0.00
Biomerica (BMRA) United States $0.008B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Alaunos Therapeutics (TCRT) United States $0.007B 0.00
SHINECO (SISI) China $0.007B 0.00
Incannex Healthcare (IXHL) Australia $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Aptorum Group (APM) United Kingdom $0.005B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Redhill Biopharma (RDHL) Israel $0.004B 0.00
Indaptus Therapeutics (INDP) United States $0.004B 0.00
Xenetic Biosciences (XBIO) United States $0.004B 0.00
CERo Therapeutics Holdings (CERO) United States $0.004B 0.00
Heatwurx (PCSA) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
Plus Therapeutics (PSTV) United States $0.003B 0.00
PainReform (PRFX) Israel $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
Jaguar Animal Health (JAGX) United States $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Conduit Pharmaceuticals (CDT) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00